Intercept Pharma (ICPT) Tops Q2 EPS by 88c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
July 29, 2021 7:00 AM EDTWorldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter
Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million
Updates to the Ocaliva U.S. Prescribing Information complete
Company provides regulatory update on NASH fibrosis program in the U.S.
Company to host conference call today at 8:30 a.m. ET
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.... More
